Scribe Therapeutics files for IPO in test of appetite for early-stage biotechs

Benjamin Oakes, Scribe Therapeutics CEO July 2, 2026 06:20 PM EDTUpdated 06:51 PM DealsIPOs Scribe Ther­a­peu­tics files for IPO in test of pub­lic ap­petite for ear­li­er-stage biotechs Kyle LaHucik Biotech Correspondent Scribe Ther­a­peu­tics filed for a Nas­daq IPO late Thurs­day. The move marks a piv­otal mo­ment for the biotech and the gene … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER